Association of Wheezing Requiring Hospitalization Before 2 Years of Age With Autoimmune Diseases During Childhood: A 15-Year Follow-up Study From Birth

PURPOSE: Wheezing in early life is most frequently caused by viral lower respiratory tract illnesses, constituting a significant disease burden in children.

This study aimed to investigate the association of wheezing in early life with autoimmune diseases throughout childhood.

METHODS: A population-matched retrospective cohort study was conducted in Korea between 2002 and 2017.

The cohort comprised 34,959 children admitted with viral wheezing before 2 years of age and an equal number of the matched unexposed children born in 2002 and 2003.

Exposed infants were defined as those hospitalized for bronchiolitis or bronchial asthma before the age of 2.

Unexposed controls were matched by sex and birth year at a 1:1 ratio, using incidence density sampling.

A Cox proportional hazard model controlled for multiple risk factors was employed.

RESULTS: The median age at hospitalization for wheeze was 9 months (interquartile range, 5–15 months), and 63% of the exposed infants were male.

Over the mean 15-year follow-up period, the incidence rate of autoimmune diseases was 74.0 and 62.2 per 10,000 person-years in the exposed and matched unexposed cohorts, respectively.

The adjusted hazard ratio for any autoimmune disease in the exposed cohort was 1.15 (95% confidence interval, 1.09–1.23) in comparison with the unexposed cohort.

The exposed cohort revealed an augmented risk for specific autoimmune diseases, including juvenile idiopathic arthritis, Kawasaki disease, Henoch-Schönlein purpura, psoriasis, idiopathic thrombocytopenic purpura, and immunoglobulin A nephropathy.

Risks were heightened for children with multiple wheezing episodes or a persistent wheezing episode after the age of 2 years.

CONCLUSIONS: This research identifies associations between early-life wheeze and the development of autoimmune diseases in childhood.

Understanding these relationships can aid in recognizing the underlying pathophysiology of early-life wheeze and childhood autoimmune diseases, contributing to management strategies for these conditions.